Navigation Links
Webster Luminal Decapolar (Coronary Sinus Fixed Curve Catheters)

ProductsWebster Luminal Decapolar (Coronary Sinus Fixed Curve Catheters)
Company Biosense Webster, a Johnson & Johnson Company
Item Webster Luminal Decapolar (Coronary Sinus Fixed Curve Catheters)
Features 
  • 5F Supra CS catheter has a short insertion length and lightweight connector which optimize insertion from the subclavian vein
  • Stainless steel wire braiding construction provides excellent torqueability
  • 7F luminal catheter for injection of contrast media into the coronary sinus
    • Description Biosense Webster is the source for a complete line of diagnostic coronary sinus catheters for left-sided mapping - all with the quality, reliability and precise performance you've come to expect from the leader in catheter technology. All of our coronary sinus catheters are specifically designed and constructed to help minimize the frustration and excess procedure time often associated with maneuvering and mapping in the coronary sinus. Each catheter is handcrafted to precise and demanding specifications, using only the finest materials. A unique multi-step process incorporating proven wire-braiding and extrusion technologies results in the excellent torque and flexibility of Biosense Webster catheters. This level of care in the manufacturing process means consistent response and performance strength, even at smaller French sizes -- characteristics vital to efficient coronary sinus placement.
    Info Biosense Webster, a Johnson & Johnson Company
    Customer Service: (800) 729-9010
    Web site: http://www.biosensewebster.com/

    Related medicine products :

    1. Webster Ruler
    2. Webster Small Anatomy Fixed Curve Catheters
    3. Webster Supra CS Decapolar (Coronary Sinus Fixed Curve Catheters)
    4. Webster Small Anatomy Deflectable Catheters
    5. Webster Coronary Sinus Deflectable Catheters
    6. Webster Quadripolar Standard Deflectable Catheters
    7. Webster Octapolar Standard Deflectable Catheters
    8. Webster Quadrapolar Standard Deflectable Catheters
    9. Webster Decapolar Standard Deflectable Catheters
    10. Webster Decapolar Coronary Sinus Deflectable Catheters
    11. Webster Parahisian octapolar catheter
    ...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
    ...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
    ...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
    ...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
    Medicine Products:
    (Date:11/21/2008)...PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc...ders overwhelmingly approved the proposals submitt...Teva Pharmaceuticals Industries Ltd. (Nasdaq: TE...verwhelming support of the transaction by the Barr...man and CEO. "We are pleased with the progress tha...
    (Date:11/21/2008)...running increases production of neural stem cells ...In experiments in mice, exercise appears to revers...s usually seen with aging, Taiwanese researchers r...in,s ability to stave off aging appears to be due ...hat is essential for the production of new brain c...
    (Date:11/21/2008)...re/ -- In a statewide survey, 33 physicians creden...ery at Presbyterian Hospital of Dallas were honore... " Super Doctors ." , , Each year, the publ...al Media, Inc. to survey more than 38,000 medical ...f you needed medical care, which doctor would you ...
    (Date:11/21/2008)...21 A prestigious group of physicia...ather in Williamsburg, VA on March 27-29, 2009 at ...l information on cutting-edge therapeutic protocol...earch advances that impact patient care. The full ...information is available at www.bioconferences.co...
    Breaking Medicine News(10 mins):Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4Health News:Exercise Keeps the Brain Young 2Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2Health News:17th Annual Congress on Women's Health Convenes March 27-29, 2009 in Williamsburg, VA 2
    ...effect of the serving environment on alcohol relat...aid, "There is no reliable evidence that intervent...n reducing injury," fatal or otherwise. There were...ng, but if you’re only able to train 50 percent or...
    ...ood tests over skin tests for detecting people wit...ests are effective, reliable and therefore holds p...s people with the dormant TB infection never actua...e, yet it becomes imperative to detect such cases ...
    ...t there is an apparent increase in premature birth...tnessed in preterm deliveries between 1995 and 200...w risk women aged 20 – 40. The study had also focu... elective deliveries. All these complications also...
    ... has made a paradigm shift from being a generic dr...growth aggressively. // "We are rapidly transform...redients) manufacturer into an innovator for devel...molecules. "We believe this strategy will deliver...
    Other Medicine News:Health News:Biocon To Shift Focus On Innovation To Accelerate Growth 2
    (Date:11/20/2008)...ov. 20 GlaxoSmithKline (N...s Food and Drug Administration (FDA) granted accel...the treatment of thrombocytopenia in patients with...ura (ITP) who have had an insufficient response to...The approval is a significant milestone for PROMAC...
    (Date:11/20/2008)...-FirstCall/ -- Bionovo, Inc.,(Nasdaq: BNVI ) an...Phase 1B,clinical trial of their lead drug candid..., at the Society for Integrative Oncology,s Fifth ...e Company,s oral presentation was selected,as a t...t of the Best of the,SIO Session on November 20, ...
    (Date:11/20/2008)...-- PAREXEL International Corporation (Nasdaq: PR...provider, today announced that it has opened an of...g and clinical research capabilities. With the add...s throughout five important biopharmaceutical cent..., Brazil, Chile, and Mexico. This expansion furthe...
    (Date:11/19/2008)...stical significance , , ISELIN, N.J., Nov. ...(Nasdaq: PARS ) today announced results from its...on (NE) drug delivery technology formulated with 3...center, randomized, double-blinded, placebo-contro...e Company,s 3% Diclofenac Diethanolamine NanoEmuls...
    Breaking Medicine Technology:FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions 3079 1Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions 3079 2Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions 3079 3Massive American Red Cross Tornado Relief Effort Spans Five States 11169 1Massive American Red Cross Tornado Relief Effort Spans Five States 11169 2Customer Experience Conference Feb 25 27 3A Sharing New Insights on Winning Customer Loyalty 11165 1Customer Experience Conference Feb 25 27 3A Sharing New Insights on Winning Customer Loyalty 11165 2Best Practice Database 3A Complimentary Excerpt of Three Sales Force Excellence Studies 11162 1Best Practice Database 3A Complimentary Excerpt of Three Sales Force Excellence Studies 11162 2
    ....--(BUSINESS WIRE)--Apr 25, 2007 - Geron,Corporati...ations,on the role of telomerase and telomeres in ...cer Research (AACR) Annual Meeting in,Los Angeles....mere,and telomerase biology reflecting the growing...omerase as a universal cancer,target for drug and ...
    ...--(BUSINESS WIRE)--Apr 25, 2007 - BioDelivery,Scie...today,statistically significant results with BEMA(...pain in its pivotal Phase III efficacy,clinical tr...evement of the primary efficacy endpoint of the tr...compared to placebo., The results demonstrated tha...
    Other Medicine Technology:Telomerase Presentations at the AACR 2007 Annual Meeting 2Telomerase Presentations at the AACR 2007 Annual Meeting 3Telomerase Presentations at the AACR 2007 Annual Meeting 4BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 2BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 3BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 4BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 5BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 6